1). These programs include an anticancer RNA oligonucleotide that originated from the Korea Advanced Institute of Science and Technology (KAIST) and oncolytic adenoviruses discovered at the ...

The Korean Food and Drug Administration approved OliX’s investigational new drug (IND) application for OLX101 in January 2017, and a clinical-trial authorization application to the European ...